ADA 2018

JUN 25, 2018

ORLANDO, FLORIDA
FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements. They are based on current assumptions and expectations that involve
uncertainties or risks. These uncertainties and risks include, but are not limited to, those described in the filings we make with the
U.S. Securities and Exchange Commission (SEC). Actual results may differ materially from anticipated results. Forward-looking
statements are made as of today's date, and we undertake no duty to update them or any of the information contained in this
presentation.

2018 ADA | Orlando, FL | 2

HOOMAN HAKAMI
EXECUTIVE VICE PRESIDENT & PRESIDENT
DIABETES GROUP

2018 ADA | Orlando, FL | 3

DIABETES
Strong legacy &
GROUP brand … highest
In many ways,
EXECUTIVE just getting
share position in started
SUMMARY almost a decade

Above Sustainability
corporate of growth
average growth
• Sensor pull-through & conversion • High differentiation & profitability
of MDI in core pump BU we’ve dramatically improved

• Launch of stand-alone CGM • Innovation in decision support &

targeting $1B+ category growing patient engagement
30%
• Outcomes focus – in products & go-
to-market

2018 ADA | Orlando, FL | 4

DIABETES STRUCTURE & OPERATING FRAMEWORK
REPOSITIONING THE BUSINESS FOR ABOVE CORPORATE AVERAGE GROWTH

Administrator
GROUP
Diabetes Group

Focus
Emerging Technologies
Disease / IPU
DIVISION

Focused
Advanced Insulin
Management (AIM) Multiple Daily Injection Non-Intensive Diabetes
Solutions (MDIS) Therapies (NDT)

Insulin pump therapy

Standalone CGM Professional CGM
systems
PRODUCT LINE

Diabetes mgmt.
Integrated CGM Injection port
programs & services

Consumables & Diabetes mgmt.

accessories programs & services

Diabetes mgmt.
programs & services

2018 ADA | Orlando, FL | 5

EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT

DISEASE STATE TYPE 2 TYPE 1

REGIMEN DIET & EXERCISE ORALS BASAL PREMIX MDI PUMPS
PREVALENCE 60MM 110MM 20MM 15MM 20MM 1.1MM

AIM
Core business

AIM
Advanced Insulin Management GOAL
 Pumps & CGM
 ~70% global share
 Patients Served: T1D & T2D on pumps Artificial Pancreas  8% penetrated
 Call point: Endocrinologists as standard of care
 Solutions: Insulin pump therapy,
consumables & accessories

2018 ADA | Orlando, FL | 6

THE MINIMED™ 670G
SYSTEM
NOW APPROVED
FOR CHILDREN 7+
Features our most advanced
SmartGuard™ technology,
which constantly self-adjusts
to allow patients to spend
more Time in Range (TIR)

Includes our newest

and most accurate
GuardianTM Sensor 3

2018 ADA | Orlando, FL | 7

NEW CE MARK!
THE MINIMED™
670G SYSTEM
FOR CHILDREN 7+
Advances the ability to automatically
suspend & resume insulin delivery to the
next level by automating self-adjusting
basal insulin every 5 minutes – providing the
most advanced algorithm that proactively
drives Time in Range improvement.

2018 ADA | Orlando, FL | 8

VALUE-BASED HEALTHCARE PARTNERSHIP

PREFERRED PARTNERSHIP STATISTICS

From To
Share 70% 92%
Revenue ↑
EBITA ↑

VALUE BASED HEALTHCARE AGREEMENT

COHORTS: PATIENTS ON PUMP THERAPY

COMPARISON GROUP: MDI PATIENTS
OUTCOME MEASURES: HOSPITALIZATIONS & TOTAL COST

• 27% REDUCTION IN PREVENTABLE HOSPITALIZATIONS

Year 1

• UP TO 14% REDUCTION IN TOTAL MEDICAL COSTS

• SHARED SAVINGS BETWEEN UHG & MEDTRONIC

20182018
Investor Day | FL
ADA | Orlando, 9|9
THE NEW MINIMEDTM 670G SYSTEM PERFORMANCE GUARANTEE
FLAT REIMBURSEMENT MODEL TO MITIGATE HOSPITAL COSTS Year 3
Year 2
New
Year 1 program
for payers
The MiniMedTM 670G System
Performance Guarantee

$25,000
total reimbursement value per patient over 4 years

Diabetes-related Inpatient Diabetes-related Emergency

Hospitalization $6000 Room Admission $2500
Inpatient hospitalization claim coded DRG ER visit coded with primary ICD-10 diagnosis of E10*
of 637, 638, or 639 (E1010-E109) type 1 diabetes, as specified by 2018 CMS ICD-10-CM

2018 ADA | Orlando, FL | 10

DISRUPTIVE CLOSED LOOP ECOSYSTEM

Launched Near Long GOALS

ALGORITHM

MM670G System Advanced HCL Personalized CL Limited patient

Outcomes Auto-correction bolus Advanced adaptation interaction
Peds indication >80% TIR goal >85% TIR goal
SENSOR

Guardian Sensor 3 Project Harmony Project Unity

Arm labeling Adaptive cals & Miniaturization, no cals, Wear & forget
9% MARD non-adjunctive 10-14 d wear , disposable
INSIGHTS USABILITY

CareLink SmartPhone App

Web-based Data viewing &
Project Duo Simple &
data mgmt. pump control
Integrated canula
& sensor
discreet
System Performance Virtual Support Proactive Triage
Report
Augmented assistance & Customer Service & HCP Differentiated
Data-guided system & AI guided optimization preventative mgmt Outcomes
behavior optimization

Note: future concepts; not investigational nor commercially available 2018 ADA | Orlando, FL | 11
LAURA STOLTENBERG
VICE PRESIDENT & GM
MULTIPLE DAILY INJECTION SOLUTIONS

2018 ADA | Orlando, FL | 12

EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT

DISEASE STATE TYPE 2 TYPE 1

REGIMEN DIET & EXERCISE ORALS BASAL PREMIX MDI PUMPS
PREVALENCE 60MM 110MM 20MM 15MM 20MM 1.1MM

MDIS
Adjacent category
 Personal CGM

MDIS
Multiple Daily Injection Solutions
GOAL
 <5% share
 ~20% penetrated
 Patients Served:
Smart, connected
T1D & T2D on multiple daily injections solutions that
MDIS Solutions
 Call point: Insulin prescribing empower patients &  Therapy Innovation
PCPs/GPs & Endos
help drive outcomes  Decision Support
 Solutions:
Standalone CGM, injection port  Patient Engagement

2018 ADA | Orlando, FL | 13

GUARDIANTM CONNECT WITH SUGAR.IQ
LAUNCHING THE MDIS BUSINESS

Expanding Access
 First stand-alone CGM launched
 20MM MDI patients globally

Empowering Patients with Smarter Tools

 Predictive alerts + Sugar.IQ Insights
 No dedicated receiver … 12 month transmitter
 Arm indication … enhanced accuracy (9.1% MARD)

Designed to Help Improve Outcomes

 ↑↑ time in range
 ↓↓ hypo / hyperglycemia frequency

Prediction feature available in a future release

Data for presentation purposes only
2018 ADA | Orlando, FL | 14
SMART CGM HELPS MDI PATIENTS MAKE SMARTER DECISIONS
SO THEY CAN FOCUS ON LIFE, NOT ON LEVELS

In-Room Video URL: https://youtu.be/Cj3ksIs1OAQ

2018 Investor Day | 15
CLINICAL OBSERVATIONS
BETTER BEHAVIOR LEADING TO POSITIVE OUTCOMES

AGGREGATE DATA p =0.01 p <0.001 p <0.001

256 Total Users

Time
In 30 mins 6 mins
11,356 Calendar days
Range per day per day

Users with 2+ weeks after using Sugar.IQ

231 of data
Time >180 mg/dL
(Avg. per day)
Time <70 mg/dL
(Avg. per day)

INSIGHTS p <0.001 p <0.001

10,761 Insights Generated

Hypo
+ 1.22 0.95
655 Hypo-related Insights Hyper episodes episodes

# of episodes High Episodes / Month Low Episodes / Month

699 Hyper-related Insights (180 mg/dL > 120 mins) (70 mg/dL > 20 mins)

Usage of Sugar.IQ app was analyzed based on data from 256 randomly offered real-world MiniMed 530G users from April to August 2017
2018 ADA | Orlando, FL | 16
SUGAR.IQ DIABETES ASSISTANT
AI PERSONALIZATION = ACTIONABLE INSIGHTS

AI-Based Assistant Retrospective Insights reveal hidden patterns

continually analyzes
multiple data sources

INSULIN FOOD MOTIVATIONAL ROUTINE & TIME

INSIGHTS INSIGHTS INSIGHTS OF DAY
INSIGHTS

Glycemic My Data
Assist tracks time in
lets patients range and
track glucose other key
response to metrics in real LOW SG FORECAST
new foods and time Hypo prediction up to 4
routines hours in advance

2018 ADA | Orlando, FL | 17

BUILDING A COMPLETE ECOSYSTEM FOR MDI PATIENTS

Launched Near Long GOALS

Guardian Connect +
SENSOR

Project Harmony Project Unity Comfortable &

Guardian Sensor 3 Adaptive calibrations & Smaller, no cals,
Arm label, 9% MARD non-adjunctive 10-14d, disposable Reliable
360o DATA

Patient Logging Automated Capture Contextual

Multiple in-app tools Insulin dose capture + Fully automated based 360o
meals, activity, insulin advanced food logging on contextual signals Patient View
Glucose
INSIGHTS

Sugar.IQ (US) Prediction Therapy Guidance

Know. Predict.
Actionable AI-based 4 hour forecast AI-based meal and
glucose insights ~90% accuracy correction bolus Coach.
ECOSYSTEM

Physician Patient Care Plans

Web-based Interactive HCP+patient
Population Management Linked Ecosystem &
Population-level
data mgmt. for remote therapy
management tools
Optimized outcomes
optimization

Note: future concepts; not investigational nor commercially available

2018 ADA | Orlando, FL | 18
SHERI DODD
VICE PRESIDENT & GM
NON-INTENSIVE DIABETES THERAPIES

2018 ADA | Orlando, FL | 19

EXPANDING FROM PUMPS & SENSORS TO DIABETES MANAGEMENT

DISEASE STATE TYPE 2 TYPE 1

REGIMEN DIET & EXERCISE ORALS BASAL PREMIX MDI PUMPS
PREVALENCE 90M 90M 15M 15M 16M 1.1M

NDT
 Diagnostic & intermittent CGM
 <1% share
NDT
Non-intensive Diabetes Therapies
 <1% penetration
GOAL  Patients Served: T2D
 Call point: PCPs/GPs
 New market opportunity
Glucose as a  Solutions:
Professional diagnostic CGM
Vital Sign

2018 ADA | Orlando, FL | 20

MEDTRONIC CARE MANAGEMENT SERVICES + NON-INTENSIVE DIABETES THERAPIES
ADDRESSING THE NEEDS OF THE CHRONIC COMORBID POPULATION

5,600,000+
Telehealth
Patient Months
MCMS NDT
19 Years
Developing the
Telehealth
Market

95,000+
Members/
patients
on Service

 Integrated Care Management

Nurses, Certified Heart Failure
Nurses
 >20 Disease Management Protocols
(physical and mental health)
 Clinical decision support software

2018 ADA | Orlando, FL | 21

MEDTRONIC CARE MANAGEMENT SERVICES + NON-INTENSIVE DIABETES THERAPIES
SYNERGY EXAMPLE
RIGHT TOOLS – RIGHT PATIENTS
MCMS identifies Complex Chronic HIGHEST ACUITY
Comorbid Population using risk  Remote Patient Monitoring
stratification methodology  Guardian Connect
 MiniMed 670G

MCMS further Risk Stratifies

MID-LEVEL ACUITY
populations into Cohorts  Guardian Connect / Sugar.IQ
(inc. HF, COPD, HTN, Diabetes)  Inner Circle
 Patient Coaching
 Remote Patient Monitoring

LOW ACUITY
Further Risk Stratification to identify  iPro2 with Pattern Snapshot + FoodPrint
clinical decision support tools to  Patient Coaching
inform care pathway

IMPROVE OUTCOMES – LOWER COSTS

2018 ADA | Orlando, FL | 22
NON-INTENSIVE DIABETES THERAPIES
THERAPY INNOVATION PIPELINE

INVESTING FOR FUTURE GROWTH

LAUNCHED AND DRIVING
CURRENT GROWTH FY19 / FY20 BEYOND

Medtronic
iPro Intelligent
Therapy
Recommendations

Personalized Real Time Coaching

Guidance

Medtronic
Envision Pro Medtronic Envision
Real Time

Note: investigational device only

Note: Future concepts; not investigational nor commercially available
2018 ADA | Orlando, FL | 23
HOOMAN HAKAMI
EXECUTIVE VICE PRESIDENT & PRESIDENT
DIABETES GROUP

2018 ADA | Orlando, FL | 24

OUR VALUE PROPOSITION ACROSS ALL BUSINESSES

Therapy Innovation Decision Support Patient Engagement VBHC Contracting

2018 ADA | Orlando, FL | 25

DIABETES GROUP
CONSISTENT, SUSTAINABLE, GROWTH ABOVE CORPORATE AVERAGE
CATEGORY MARKET
GROWTH DRIVERS SALES1 CAGR2

Closed Loop as Standard-of-Care ~$3.5B ~10%

THERAPY Increased CGM attachment rates;
INNOVATION
Drive MDI conversions; International expansion
CONSISTENT EXECUTION

Sustained Launched Stand-Alone CGM ~$1B ~26%

Growth Smart CGM system
GLOBALIZATION focused on outcomes
Above
Corporate
Average Expansion into Type 2 ~$0.1B ~70%
Increase diagnostic CGM
ECONOMIC glucose as a vital sign in the management of T2
VALUE

Globalization & Enterprise Excellence

Clinics & care management expansion globally
Leverage MDT Footprint for CGM & Customer Care
ENTERPRISE
EXCELLENCE

1. FY18 market estimates

2. FY17-FY22 growth estimates 2018 ADA | Orlando, FL | 26
ADA 2018
JUN 25, 2018
ORLANDO, FLORIDA
APPENDIX
2018 ADA | Orlando, FL | 29